Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
IDF begins destroying homes used by Hezbollah as forces move deeper into southern Lebanon - 2Civil rights leader Jesse Jackson hospitalized, family requests prayers
- 3Oldest evidence of human fire-making discovered at site in England
- 4NATO official says members often aren't buying weapons together, and it's a mistake
- 5Netflix Faces Wider Fallout After Italy Court Orders Refunds, Price Cuts
- Iran war fuels fears of new inflation wave among German consumers
- Who is Artemis? Meet the Greek goddess who inspired NASA's return to the moon
- NASA study shows how satellite 'light pollution' hinders space telescopes
- Find the Marvels of the World with These Travels
- See a half-lit moon shine among the stars of Aquarius on Nov. 27
- Turning into a Sharp Financial backer: Individual budget Wins
- Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
- Step by step instructions to Recognize the Distinction Between Lab Jewels and Precious stone Simulants
- Figure out How to Augment the Advantages of a Web-based Degree
